

the leading answer to pet cancer



Stephanie Correa, DVM

- BRAND NEW - ACCC oncologists have clinical experience with Palladia
- The first FDA approved medication for the treatment of cancer in veterinary medicine
- A targeted therapy indicated for the treatment of dogs with recurrent grade 2 and 3 mast cell tumors
- Made by Pfizer who will provide the drug to ACCC at no cost through December of 2009

www.animalcancercareclinic.com

Stephanie Correa, DVM
Board Certified in Medical Oncology

Pedro Dominguez, DVM
Board Certified in Medical Oncology
Board Eligible in Radiation Oncology


Maria Camps, DVM
Board Certified in Medical Oncology
Board Certified in Internal Medicine

Carrie Kosarek, DVM, MS
Board Certified in Medical Oncology

COMING SOON

1122 NE 4th Avenue, Ft. Lauderdale FL 33304

FORT LAUDERDALE



T+ 305.666.4142 F+ 954.653.4644

6394 S. Dixie Hwy., Miami FL 33143

SOUTH MIAMI

T+ 305.652.0448 F+ 954.653.4644

20290 NW 2nd Ave. (441), Miami FL 33169

NORTH MIAMI

T+ 954.421.5099 F+ 954.653.4644

372 S. Powerline Rd., Deerfield Beach FL 33442

DEERFIELD BEACH

T+ 561.967.5966 F+ 954.653.4644

3421 Forest Hill Blvd., W. Palm Beach FL 33406

WEST PALM BEACH

June 2009 – Issue No. 2

In This Issue

- **Palladia: A New Treatment Option for Dogs with Mast Cell Disease**

A Cancer Drug Breakthrough, Palladia is:

Palladia: A New Treatment Option for Dogs with Mast Cell Disease

Maria Camps, DVM

Diplomate ACVIM (Oncology and Internal Medicine)

The Animal Cancer Care Clinic is extremely excited to be one of the first veterinary cancer groups in the country to offer Palladia as a new treatment modality for dogs with Mast Cell Tumors (MCT). Dogs that qualify as candidates to receive this drug will receive the drug at no cost to the client. We will be collecting efficacy data for Pfizer Animal Health, who will provide the drug to ACCC.



Palladia is the first FDA approved medication for the treatment of cancer in veterinary medicine. The generic name of Palladia is Toseranib Phosphate and it is a targeted therapy similar to other state of the art anticancer drugs that are being developed for people. Palladia belongs to the tyrosine kinase inhibitor (TKI) class of compounds and it works by blocking the activity of key receptors important for the development of blood vessels that supply tumors, as well as receptors critical for tumor survival. Palladia is currently indicated for the treatment of grade II or III MCT with local recurrence with or without regional lymph node involvement, or distant spread. The Palladia trial (London et al, Clin Cancer Res 2009) found that about 60% of dogs with MCT had their tumors halt their growth, partially respond or completely disappear.

Mast cell tumors are classified as Grade I, II or III, with grade III being the most severe. Because of their unpredictable nature, malignancy is usually assumed until proven otherwise and wide margins must be obtained when removing these tumors. Immunohistochemistry to assess the tumor's proliferation markers may help further characterize the tumor's biological behavior. Regional lymph nodes, liver and spleen should also be evaluated. To date, surgical excision and radiation therapy are the most successful treatment options for mast cell tumors. Unfortunately, recurrent local disease and metastatic disease remain a challenge to treat, and systemic adjuvant chemotherapy is offered in those cases. With the addition of Palladia as a treatment modality for patients with mast cell disease, another option now exists for the treatment of chemotherapy resistant disease or surgically non-resectable disease.

Dr. Correa and I both have clinical experience with this drug, and we are two of the few people in this country with experience in using this new medication. Palladia is an oral preparation that is administered every other day by the owners at home. At this time, it is available to board certified specialists practicing medical oncology. Side effects of Palladia can be serious, and scheduled monitoring is required, but most side effects appear to be manageable. The most common side effects include lethargy, decreased appetite, vomiting and diarrhea. Life-threatening adverse events are rare but have been described and early intervention is critical. The price for the drug and its monitoring will likely be comparable to the cost of the conventional chemotherapy protocols used for this disease.

The Palladia program will continue through December of 2009 and drug fees will be waived during this time, with only consultation fees, staging tests, and drug dispensing fees being applied during the Palladia program period. Please feel free to contact one of the ACCC oncologists (Drs. Correa, Dominguez, Kosarek, Camps) if you have further questions or have your client set up an appointment with us to determine if their pet will be a candidate to receive Palladia. With your continued support and partnership, we are determined to be the *leading answer to pet cancer*.

